Literature DB >> 9370363

Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.

I T Weber1, J Wu, J Adomat, R W Harrison, A R Kimmel, E M Wondrak, J M Louis.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) protease hydrolysis of the Gag CA-p2 cleavage site is crucial for virion maturation and is optimal at acidic pH. To understand the processing of the CA-p2 site, we have determined the structure of HIV-1 protease complexed with an analog of the CA-p2 site, the reduced peptide inhibitor Arg-Val-Leu-r-Phe-Glu-Ala-Ahx-NH2 [r denotes the reduced peptide bond and Ahx 2-aminohexanoic acid (norleucine), respectively]. The crystal structure was refined to an R-factor of 0.17 at 0.21-nm resolution. The crystals have nearly the same lattice as related complexes in P2(1)2(1)2(1) which have twofold disordered inhibitor, but are in space group P2(1). and the asymmetric unit contains two dimers of HIV-1 protease related by 180 degrees rotation. An approximate non-crystallographic symmetry has replaced the exact crystal symmetry resulting in well-ordered inhibitor structure. Each protease dimer binds one ordered inhibitor molecule, but in opposite orientations. The interactions of the inhibitor with the two dimers are very similar for the central P2 Val to P2' Glu residues, but show more variation for the distal P3 Arg and P4' Ahx residues. Importantly, the carboxylate oxygens of Glu at P2' in the inhibitor are within hydrogen-bonding distance of a carboxylate oxygen of Asp30 of the protease suggesting that the two side chains share a proton. This interaction suggests that the enzyme-substrate complex is additionally stabilized at lower pH. The importance of this interaction is emphasized by the absence of polymorphisms of Asp30 in the protease and variants of P2' Glu in the critical CA-p2 cleavage site.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370363     DOI: 10.1111/j.1432-1033.1997.00523.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  14 in total

1.  Optimized labeling of 13CHD2 methyl isotopomers in perdeuterated proteins: potential advantages for 13C relaxation studies of methyl dynamics of larger proteins.

Authors:  R Ishima; J M Louis; D A Torchia
Journal:  J Biomol NMR       Date:  2001-10       Impact factor: 2.835

2.  Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease.

Authors:  Oscar Alvizo; Seema Mittal; Stephen L Mayo; Celia A Schiffer
Journal:  Protein Sci       Date:  2012-06-05       Impact factor: 6.725

3.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

4.  Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease.

Authors:  Michael D Altman; Ellen A Nalivaika; Moses Prabu-Jeyabalan; Celia A Schiffer; Bruce Tidor
Journal:  Proteins       Date:  2008-02-15

5.  A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease.

Authors:  Ian W Windsor; Ronald T Raines
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-06-27       Impact factor: 7.652

6.  Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging.

Authors:  Nelly Morellet; Sabine Druillennec; Christine Lenoir; Serge Bouaziz; Bernard P Roques
Journal:  Protein Sci       Date:  2005-02       Impact factor: 6.725

7.  Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  DOCK 6: Impact of new features and current docking performance.

Authors:  William J Allen; Trent E Balius; Sudipto Mukherjee; Scott R Brozell; Demetri T Moustakas; P Therese Lang; David A Case; Irwin D Kuntz; Robert C Rizzo
Journal:  J Comput Chem       Date:  2015-06-05       Impact factor: 3.376

9.  Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Keith Romano; Celia A Schiffer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease.

Authors:  Rieko Ishima; Qingguo Gong; Yunfeng Tie; Irene T Weber; John M Louis
Journal:  Proteins       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.